about
Adjuvants: Classification, Modus Operandi, and LicensingChoice and Design of Adjuvants for Parenteral and Mucosal VaccinesImmunotherapy advances for glioblastomaToll-like receptors in antiviral innate immunityDendritic cell-based vaccine efficacy: aiming for hot spotsMetal-Based Nanoparticles and the Immune System: Activation, Inflammation, and Potential ApplicationsThe Immunomodulatory Role of Adjuvants in Vaccines Formulated with the Recombinant Antigens Ov-103 and Ov-RAL-2 against Onchocerca volvulus in MiceImmune Adjuvant Effect of Molecularly-defined Toll-Like Receptor LigandsPolyarginine induces an antitumor immune response through binding to toll-like receptor 4.The TLR2 Binding Neisserial Porin PorB Enhances Antigen Presenting Cell Trafficking and Cross-presentation.A potential protein adjuvant derived from Mycobacterium tuberculosis Rv0652 enhances dendritic cells-based tumor immunotherapy.Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival.Pancreatic cancer-specific cell death induced in vivo by cytoplasmic-delivered polyinosine-polycytidylic acid.Targeting the tumor microenvironment to enhance antitumor immune responsesResiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma.Differential adjuvant activities of TLR7 and TLR9 agonists inversely correlate with nitric oxide and PGE2 productionPlasmacytoid dendritic cells lead the charge against tumors.Distinct TLR adjuvants differentially stimulate systemic and local innate immune responses in nonhuman primates.Formulation and delivery of vaccines: Ongoing challenges for animal management.Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancerSynergy between RA and TLR3 promotes type I IFN-dependent apoptosis through upregulation of TRAIL pathway in breast cancer cells.A cell-based microarray to investigate combinatorial effects of microparticle-encapsulated adjuvants on dendritic cell activation.Chitin, chitosan, and glycated chitosan regulate immune responses: the novel adjuvants for cancer vaccineEnhancement of anti-tumor effect of particulate vaccine delivery system by 'bacteriomimetic' CpG functionalization of poly-lactic-co-glycolic acid nanoparticlesBugs in the system.Recombinant Nonstructural 3 Protein, rNS3, of Hepatitis C Virus Along With Recombinant GP96 Induce IL-12, TNFα and α5integrin Expression in Antigen Presenting Cells.Tumor lysate-loaded biodegradable microparticles as cancer vaccines.A review of dendritic cell therapy for cancer: progress and challenges.Recent progress in peptide vaccination in cancer with a focus on non-small-cell lung cancer.Toll gates: An emerging therapeutic target.Cross-talk between pathogen recognizing Toll-like receptors and immunoglobulin Fc receptors in immunity.Cancer testis antigen and immunotherapy.Prostate carcinoma cells LNCaP and glucan cooperate in induction of cytokine synthesis by dendritic cells: effect on natural killer cells and CD4+ lymphocytes activation.Development of Peptide Vaccines in Dengue.Preparation of tumor antigen-loaded mature dendritic cells for immunotherapy.GK-1 improves the immune response induced by bone marrow dendritic cells loaded with MAGE-AX in mice with melanoma.Comparing the effect of Toll-like receptor agonist adjuvants on the efficiency of a DNA vaccine.Pharmacological Tools to Activate Microglia and their Possible use to Study Neural Network Patho-physiology.Natural toll-like receptor agonists in prophylactic vaccines for dendritic cell activation.Induction of T cell responses and recruitment of an inflammatory dendritic cell subset following tumor immunotherapy with Mycobacterium smegmatis.
P2860
Q26747586-6AA335A2-294B-4ABC-AE1B-5CB6BC547357Q26783488-0E83E0C7-76AB-441E-BC65-47D196213013Q26866513-6719FFD7-8094-4161-BBF4-FC5B4A1D88A7Q27011462-2524589F-FA53-4812-92E6-E719BBFD6904Q28082680-50DB31C4-CBE3-4B36-9492-9F6E4B7FBB98Q28396375-838C2431-94C7-4750-B3AA-2EC163AD7CE9Q28552440-CFFAF7A6-B3C7-4D5B-A618-743DB1E36B1FQ28972540-4C4AEDEE-E5C2-4D4E-B0E3-3BE1C9BB14ADQ30585455-9DF039BB-5E94-42B5-9F1D-6F848B573D2CQ33673210-845EF147-CEEF-4730-809B-9A3AD0C1BB7AQ34015759-26D32DEF-F03B-4D5E-84FC-3095C11FA68BQ34289273-7DDECBF0-80BA-4919-8D44-1117389F64F4Q34438516-D842213B-20B2-4D38-A51C-976A98671E04Q35176307-97EA4F24-A17E-4AC0-9AD3-10FB8A0B08C5Q35218562-3641E724-0CE7-4458-83AA-A891379A3C79Q35392417-0D884F1F-D2FB-49E6-8E47-84FE0C66A937Q35699010-4E74C709-00F4-4653-8271-26281AB0B0F2Q35849215-92240838-5426-4C3B-8722-5194DA986AB3Q36470265-58D19336-B1B7-4377-B6DB-666258DD69AEQ36476394-269495C5-B65A-42C4-9200-87199AC44A84Q36586558-DDE08AF6-C1CD-44A2-B8C2-5B94A57D13C5Q36684447-A861A207-4283-467C-AD82-D5D9C2D2D0EBQ36702887-7B9D7B7C-9A76-4B5B-92C1-6633E169A3AAQ36822999-4C041814-5438-4A05-9F20-606309C51C08Q37108455-252D0A86-BE53-4ACE-96E6-B8A09FCC5E55Q37158810-667137F1-6348-4150-8718-DF6E592B1469Q37670779-6D4AF635-4DD9-422D-AEB3-9A1917F3AC0DQ38099612-421EDAF9-B192-410D-A2D1-F1EC76BC0437Q38168904-80830CBF-844A-43C3-9869-179E16A9E1A0Q38333830-8F4D6317-0B98-4813-B900-1CE15B52300EQ38615394-2D1D45F1-110E-40D2-B9C3-F7DB226C2950Q38912232-75DB3C9D-CF8A-4932-9201-E19DFF5A21EDQ39499334-036A66E0-113D-42BB-B531-A7EBC802772DQ40038715-4B03AA60-C38A-4E80-9287-660C4401063BQ41855097-53A481CA-000A-4CE6-BACC-5A19A367C27CQ41901253-56258C57-8623-44C1-92CA-F9145DDD337CQ42235064-0461CA73-125A-4507-B752-FF331B32FD6EQ42712047-25B37D5D-276F-42A6-943F-81AED7864811Q45921466-CAC61BAD-CE75-4B26-9150-B7BC95CC9F8EQ47601017-407A7FF6-0397-40E9-A809-13B887B5D675
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Toll-like receptor agonists: are they good adjuvants?
@ast
Toll-like receptor agonists: are they good adjuvants?
@en
Toll-like receptor agonists: are they good adjuvants?
@nl
type
label
Toll-like receptor agonists: are they good adjuvants?
@ast
Toll-like receptor agonists: are they good adjuvants?
@en
Toll-like receptor agonists: are they good adjuvants?
@nl
prefLabel
Toll-like receptor agonists: are they good adjuvants?
@ast
Toll-like receptor agonists: are they good adjuvants?
@en
Toll-like receptor agonists: are they good adjuvants?
@nl
P2093
P2860
P1433
P1476
Toll-like receptor agonists: are they good adjuvants?
@en
P2093
Nikhil B Sawhney
Nina Bhardwaj
Sacha Gnjatic
P2860
P304
P356
10.1097/PPO.0B013E3181EACA65
P577
2010-07-01T00:00:00Z